Report cover image

Global Dupilumab Injection Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 195 Pages
SKU # APRC20280120

Description

Summary

According to APO Research, the global Dupilumab Injection market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Dupilumab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Dupilumab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Dupilumab Injection market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Dupilumab Injection is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Dupilumab Injection market include Regeneron and Sanofi etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Dupilumab Injection, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Dupilumab Injection, also provides the sales of main regions and countries. Of the upcoming market potential for Dupilumab Injection, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Dupilumab Injection sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Dupilumab Injection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Dupilumab Injection sales, projected growth trends, production technology, application and end-user industry.

Dupilumab Injection Segment by Company

Regeneron
Sanofi
Dupilumab Injection Segment by Type

200mg (1.14mL)/Vial
300mg (2.0 mL)/Vial
Dupilumab Injection Segment by Application

Asthma
Atopic Dermatitis
Chronic Sinusitis with Nasal Polyps
Other
Dupilumab Injection Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Dupilumab Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Dupilumab Injection market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Dupilumab Injection significant trends, drivers, influence factors in global and regions.
6. To analyze Dupilumab Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dupilumab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dupilumab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dupilumab Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dupilumab Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dupilumab Injection industry.
Chapter 3: Detailed analysis of Dupilumab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Dupilumab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Dupilumab Injection in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

195 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Dupilumab Injection Sales Value (2020-2031)
1.2.2 Global Dupilumab Injection Sales Volume (2020-2031)
1.2.3 Global Dupilumab Injection Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Dupilumab Injection Market Dynamics
2.1 Dupilumab Injection Industry Trends
2.2 Dupilumab Injection Industry Drivers
2.3 Dupilumab Injection Industry Opportunities and Challenges
2.4 Dupilumab Injection Industry Restraints
3 Dupilumab Injection Market by Company
3.1 Global Dupilumab Injection Company Revenue Ranking in 2024
3.2 Global Dupilumab Injection Revenue by Company (2020-2025)
3.3 Global Dupilumab Injection Sales Volume by Company (2020-2025)
3.4 Global Dupilumab Injection Average Price by Company (2020-2025)
3.5 Global Dupilumab Injection Company Ranking (2023-2025)
3.6 Global Dupilumab Injection Company Manufacturing Base and Headquarters
3.7 Global Dupilumab Injection Company Product Type and Application
3.8 Global Dupilumab Injection Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Dupilumab Injection Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Dupilumab Injection Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Dupilumab Injection Market by Type
4.1 Dupilumab Injection Type Introduction
4.1.1 200mg (1.14mL)/Vial
4.1.2 300mg (2.0 mL)/Vial
4.2 Global Dupilumab Injection Sales Volume by Type
4.2.1 Global Dupilumab Injection Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Dupilumab Injection Sales Volume by Type (2020-2031)
4.2.3 Global Dupilumab Injection Sales Volume Share by Type (2020-2031)
4.3 Global Dupilumab Injection Sales Value by Type
4.3.1 Global Dupilumab Injection Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Dupilumab Injection Sales Value by Type (2020-2031)
4.3.3 Global Dupilumab Injection Sales Value Share by Type (2020-2031)
5 Dupilumab Injection Market by Application
5.1 Dupilumab Injection Application Introduction
5.1.1 Asthma
5.1.2 Atopic Dermatitis
5.1.3 Chronic Sinusitis with Nasal Polyps
5.1.4 Other
5.2 Global Dupilumab Injection Sales Volume by Application
5.2.1 Global Dupilumab Injection Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Dupilumab Injection Sales Volume by Application (2020-2031)
5.2.3 Global Dupilumab Injection Sales Volume Share by Application (2020-2031)
5.3 Global Dupilumab Injection Sales Value by Application
5.3.1 Global Dupilumab Injection Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Dupilumab Injection Sales Value by Application (2020-2031)
5.3.3 Global Dupilumab Injection Sales Value Share by Application (2020-2031)
6 Dupilumab Injection Regional Sales and Value Analysis
6.1 Global Dupilumab Injection Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Dupilumab Injection Sales by Region (2020-2031)
6.2.1 Global Dupilumab Injection Sales by Region: 2020-2025
6.2.2 Global Dupilumab Injection Sales by Region (2026-2031)
6.3 Global Dupilumab Injection Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Dupilumab Injection Sales Value by Region (2020-2031)
6.4.1 Global Dupilumab Injection Sales Value by Region: 2020-2025
6.4.2 Global Dupilumab Injection Sales Value by Region (2026-2031)
6.5 Global Dupilumab Injection Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Dupilumab Injection Sales Value (2020-2031)
6.6.2 North America Dupilumab Injection Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Dupilumab Injection Sales Value (2020-2031)
6.7.2 Europe Dupilumab Injection Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Dupilumab Injection Sales Value (2020-2031)
6.8.2 Asia-Pacific Dupilumab Injection Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Dupilumab Injection Sales Value (2020-2031)
6.9.2 South America Dupilumab Injection Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Dupilumab Injection Sales Value (2020-2031)
6.10.2 Middle East & Africa Dupilumab Injection Sales Value Share by Country, 2024 VS 2031
7 Dupilumab Injection Country-level Sales and Value Analysis
7.1 Global Dupilumab Injection Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Dupilumab Injection Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Dupilumab Injection Sales by Country (2020-2031)
7.3.1 Global Dupilumab Injection Sales by Country (2020-2025)
7.3.2 Global Dupilumab Injection Sales by Country (2026-2031)
7.4 Global Dupilumab Injection Sales Value by Country (2020-2031)
7.4.1 Global Dupilumab Injection Sales Value by Country (2020-2025)
7.4.2 Global Dupilumab Injection Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.5.2 USA Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.6.2 Canada Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.8.2 Germany Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.9.2 France Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.9.3 France Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.11.2 Italy Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.12.2 Spain Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.13.2 Russia Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.16.2 China Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.16.3 China Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.17.2 Japan Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.19.2 India Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.19.3 India Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.20.2 Australia Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.24.2 Chile Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.26.2 Peru Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.28.2 Israel Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.29.2 UAE Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.31.2 Iran Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Dupilumab Injection Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Dupilumab Injection Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Dupilumab Injection Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Regeneron
8.1.1 Regeneron Comapny Information
8.1.2 Regeneron Business Overview
8.1.3 Regeneron Dupilumab Injection Sales, Value and Gross Margin (2020-2025)
8.1.4 Regeneron Dupilumab Injection Product Portfolio
8.1.5 Regeneron Recent Developments
8.2 Sanofi
8.2.1 Sanofi Comapny Information
8.2.2 Sanofi Business Overview
8.2.3 Sanofi Dupilumab Injection Sales, Value and Gross Margin (2020-2025)
8.2.4 Sanofi Dupilumab Injection Product Portfolio
8.2.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Dupilumab Injection Value Chain Analysis
9.1.1 Dupilumab Injection Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Dupilumab Injection Sales Mode & Process
9.2 Dupilumab Injection Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Dupilumab Injection Distributors
9.2.3 Dupilumab Injection Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.